Predictive value of neutrophil-to-apolipoprotein A1 ratio in all-cause and cardiovascular death in elderly non-valvular atrial fibrillation patients

Figures

• 

  Fig. 1. Flow chart for selecting patients. AF, atrial fibrillation.

• 

  Fig. 2. An un-adjusted and adjusted Kaplan-Meier survival plot of NAR quartiles regarding all-cause and cardiovascular mortality. The inverse probability weighting (IPW) method was used to adjust for age, sex, race, smoke, albumin, and malignancy (C and D). NAR, neutrophil-to-apolipoprotein A1; IPW, inverse probability weighting.

• 

  Fig. 3. Subgroup analysis of NAR on all-cause mortality. Note: The P values for interactions were 0.777, 0.338, 0.667, and 0.074 for sex, anticoagulants, statins, and type of AF, respectively (in crude model); The P values for interactions were 0.926, 0.406, 0.285, and 0.154 for sex, anticoagulants, statins, and type of AF, respectively (in model 1); The P values for interactions were 0.958, 0.394, 0.178, and 0.374 for sex, anticoagulants, and statins, and type of AF, (in model 2); The P values for interactions were 0.969, 0.404, 0.162, and 0.346 for sex, anticoagulants, statins, and type of AF, respectively (in model 3). AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio; NAR, neutrophil-to-apolipoprotein A1. Model 1: adjusted for sex, age, ethnicity, smoke, albumin, and malignancy; Model 2: adjusted for model 1 + anticoagulants, statins, hypertension, diabetes mellitus, heart failure, stroke, and vascular disease; Model 3: adjusted for model 2 + CHA2DS2-VASc, total bilirubin, alanine aminotransferase, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, red-cell distribution width, platelet count, mean platelet…

• 

  Fig. 4. Subgroup analysis of NAR on cardiovascular mortality. Note: The P values for interactions were 0.206, 0.083, 0.894, and 0.902 for sex, anticoagulants, statins, and type of AF, respectively (in crude model); The P values for interactions were 0.145, 0.113, 0.874, and 0.944 for sex, anticoagulants, statins, and type of AF, respectively (in model 1); The P values for interactions were 0.123, 0.110, 0.788, and 0.940 for sex, anticoagulants, statins, and type of AF, respectively (in model 2); The P values for interactions were 0.179, 0.143, 0.765, and 0.960 for sex, anticoagulants, statins, and type of AF, respectively (in model 3). AF, atrial fibrillation; CI, confidence interval; HR, hazard ratio; NAR, neutrophil-to-apolipoprotein A1. Model 1: adjusted for sex, age, ethnicity, smoke, albumin, and malignancy; Model 2: adjusted for model 1 + anticoagulants, statins, hypertension, diabetes mellitus, heart failure, stroke, and vascular disease; Model 3: adjusted for model 2 + CHA2DS2-VASc, total bilirubin, alanine aminotransferase, triglycerides, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, red-cell distribution width, platelet count,…